With approval from local officials in Ireland now in hand, Shire said work on a $400 million biologics plant can begin.
The rare disease drugmaker announced today that with the final planning step complete, it will begin recruiting for the 400 jobs the new plant is expected to require.
“We are pleased to have met this important milestone as we move forward in preparation to start building our new manufacturing plant,” Tim Kelly, Shire senior VP of biologics, said in a statement.
The construction on the facility, which will be able to produce clinical through commercial scale products, is expected to begin shortly and be complete in 2019. It is being built on a 120-acre site in Piercetown, County Meath, about 20 miles from Dublin.
Shire is a much larger company than it was when it announced the the plant last spring. In June it completed its $32 billion deal to acquire Baxalta. Now the company is in the process of merging Baxalta into its operations.
CEO Flemming Ornskov said in August that Shire now believes it can cut about $700 million in annual savings from the combined companies instead of the $500 million it initially promised investors. He said that about 20% will come from manufacturing as the company eliminates redundancies and finds ways to leverage the drugmakers’ combined scale of operations.
By Eric Palmer
Source: Fierce Pharma
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.